Co-investment Platform with Reduced Risk and Unmatched Liquidity

Focus and Guidelines

We are well-positioned to achieve venture returns with reduced risk and higher liquidity by investing in mid- to late-stage venture-backed healthcare companies, while also capitalizing on Asia's robust healthcare demand for the U.S.’s advanced technology to strategically create value for our portfolio companies. Our structure gives our investors the option to participate at their sole discretion in each fully underwritten deal led by a prestigious venture capital firm, providing unmatched flexibility and transparency.
 

Target Company

 

Revenue > US$20 million

Annual top line growth over 40%

Global investments with a focus on product/service commercialization in Asia

Subsector Focus

Consumer Healthcare

Diagnostics

Med Technology

Medical Devices

Profitability & Cash Flow

EBITDA > US$ 2 million

 

 


Capital raised should fund operations for at least 3 years

Vertical Focus

Ophthalmology
Cardiovascular

Cancer Diagnostics

Dentistry

Men's & Women's Health

Telemedicine

Active Involvement in Deal Lifecycle

Comprehensive and detail-oriented value-creation strategy ensures our participation in the full private equity investment process ─ from deal-sourcing to exit strategy.

Abundant connections and resources in the United States healthcare and finance industries strongly support investment deal-sourcing

Deal Sourcing

Value Creation

Deep experience in cross-border commercialization and operational management help to create value for portfolio companies

Vast network of medical and financial institutions will provide a multi-faceted exit strategy ranging from traditional IPO to strategic sales and SPACs

Exit Strategy

CONTACT US

Carnegie Hall Tower, 152 W57th Street, 49th Floor, 
New York, NY 10019

info@bridgepoint.capital

WeChat